Guggenheim Names Novavax (NVAX) its Best Idea

August 26, 2016 8:57 AM EDT
Get Alerts NVAX Hot Sheet
Price: $1.35 -1.46%

Rating Summary:
    4 Buy, 7 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade NVAX Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Guggenheim analyst William Tanner named Novavax (NASDAQ: NVAX) its Best Idea and reiterated a Buy rating and price target of $25.

Tanner commented, "We are designating NVAX shares as our Best Idea ahead of the release of top-line data (3Q16 per management guidance) from the Phase 3 Resolve trial of the RSV vaccine in older adults. If safe and effective, we believe it will become the first active vaccine marketed for preventing RSV infection. A significant, global unmet medical need should position Novavax well in negotiations with potential partners seeking ex-U.S. commercial rights, we believe. Release of the Resolve data could create substantial share volatility and we remind investors that the company possesses other assets that could also create share value, namely, the seasonal influenza vaccine and programs in other infectious diseases such as Zika"

For an analyst ratings summary and ratings history on Novavax click here. For more ratings news on Novavax click here.

Shares of Novavax closed at $6.87 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA, Hot Comments

Related Entities


Add Your Comment